Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

272
Delayed Quote. Delayed Nyse - 03/06 04:00:28 pm
100.11 USD   -2.35%
01:21a AbbVie in $21bn acquisition of cancer drug firm
03/05 JOHNSON & JOHNS : Local woman wins $5.7 million in lawsuit against J..
03/05DJBiotech Bidding War Yields Rich Price
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

05/16/2012 | 05:11am US/Eastern

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

React to this article
Latest news on JOHNSON & JOHNSON
02:06p JOHNSON & JOHNSON : Managing Sciences for Health (MSH) - Discussion
03:19a JOHNSON & JOHNSON : Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces..
01:21a AbbVie in $21bn acquisition of cancer drug firm
12:01a JOHNSON & JOHNSON : Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces..
03/05 JOHNSON & JOHNSON : Local woman wins $5.7 million in lawsuit against Johnson & J..
03/05DJBiotech Bidding War Yields Rich Price
03/05 AbbVie CEO defends Pharmacyclics deal to sceptical investors
03/05DJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- 4th Update
03/05 AbbVie CEO says new form of Humira could thwart generics
03/05 AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF